You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Foundayo ™ (orforglipron) tablet
0.8 mg / 2.5 mg / 5.5 mg / 9 mg / 14.5 mg / 17.2 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
What should patients do if they miss a dose of Foundayo™ (orforglipron)?
If a dose is missed, take the dose as soon as possible. Do not double up the next dose. If 7 or more consecutive doses are missed, reinitiate dosage escalation at a lower dosage to reduce the risk of gastrointestinal adverse reactions.
See important safety information, including boxed warning, in the attached prescribing information.
How to Proceed if a Dose of Orforglipron Was Missed?
Take orforglipron orally once daily, with or without food.1
Swallow tablets whole. Do not break, crush, or chew.1
Do not take more than one tablet per day.1
If a dose is missed, instruct patients to take the dose as soon as possible. Advise patients not to double up the next dose.1
If 7 or more consecutive doses are missed, reinitiate dosage escalation at a lower dosage to reduce the risk of gastrointestinal adverse reactions.1
Eli Lilly and Company cannot provide treatment recommendations on missed doses beyond the approved prescribing information.
Enclosed Prescribing Information
References
1FOUNDAYO™ (orforglipron) tablets, for oral use [prescribing information]. Indianapolis, IN: Lilly USA, LLC.
Date of Last Review: April 01, 2026